Trial Profile
A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Voclosporin (Primary) ; Mycophenolate; Steroids
- Indications Lupus nephritis
- Focus Registrational; Therapeutic Use
- Acronyms AURORA 1
- Sponsors Aurinia Pharmaceuticals
- 15 Nov 2023 Results assessing to compare and analyze the safety and efficacy data in propensity-matched patients from the ALMS (n=96) and AURORA 1 (n=96), presented at the ACR Convergence 2023.
- 15 Nov 2023 Results from the AURORA 1 and AURORA 2 assessing Long-term Safety and Efficacy of Voclosporin in Black Patients with Lupus Nephritis, presented at the ACR Convergence 2023
- 15 Nov 2023 Results of pooled analysis of Phase 2 AURA-LV and Phase 3 AURORA 1 studies assessing outcomes in patients with UPCR >-2 g/g, presented at the ACR Convergence 2023.